Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isis Pharmacueticals

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

The logistics of orphan drugs

Managing a rare disease global access programme, the goal is to minimise risk and get the drug to the patient on time

- PMLiVE

Rare disease strategy for the UK launched

Aims to improve understanding and boost research

- PMLiVE

Roche CMO joins Google health venture Calico

Hal Barron among four new appointments

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Roche - Basel

Roche cuts $1bn deal on cancer therapy with Immatics

Licenses series of early-stage oncology immunotherapy programmes

- PMLiVE

Roche names head of European comms

Promotes Susie Hackett

Shire Basingstoke

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal

Shire Basingstoke

Shire mulls UK job cuts

Enters “employee consultation process” for research site in Basingstoke

- PMLiVE

Orphan status for Stem Cell’s leukaemia drug

Tigecycline wins FDA rare disease designation

- PMLiVE

FDA clears Roche’s breakthrough drug Gazyva

First drug approved in US under new scheme

Roche - Basel

Roche signs €400m superbug deal

Buys rights to investigational antibiotic from Polyphor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links